Director Leon Recanati Buys $292K of Evogene Stock at $0.635
EVGN sits 62% above its 52-week low of $0.37 on light trading volume (0.3× avg).
Summary
Director Leon Recanati bought $292,100 worth of Evogene shares at $0.635, increasing his stake to 1.34 million shares.
Key Events · Ownership and Investor Activity · EVGN
-
Director Buys $292K in Open Market
On August 11, 2026, Leon Recanati purchased 460,000 ordinary shares at $0.635 per share, for a total of $292,100.
-
Stake Increases to 1.34M Shares
Following the purchase, Recanati directly owns 1,343,886 shares, up from 883,886 shares.
-
Purchase Amid Proxy Fight
The buy comes as activist shareholders seek to replace most of the board, and the company has an active ATM offering.
-
Transaction Represents ~3% of Market Cap
The $292,100 purchase is significant relative to Evogene's $9.7 million market capitalization.
Analysis · EVGN · Industrial Applications And Services
On August 11, 2026, Director Leon Recanati bought 460,000 shares at $0.635 per share, totaling $292,100. This substantial open-market purchase by a board member represents about 3% of the company's market cap. It comes amid a proxy fight with activist shareholders and a heavily dilutive ATM offering, suggesting the director is putting personal capital behind the company's defense.
At the time of this filing, EVGN was trading at $0.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $9.7M. The 52-week trading range was $0.37 to $1.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.